TG Therapeutics Inc (TGTX) Stock Analysis

TG Therapeutics Inc (TGTX) is a publicly traded company in the HEALTHCARE sector. It trades at $36.64, carries a market capitalization of $5.73B, a price-to-earnings ratio of 13.08. This page summarizes the public market data, fundamentals, and frequently asked questions for TGTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

TG Therapeutics Inc currently has a Bullish sentiment score of 0.41.

About TG Therapeutics Inc

TG Therapeutics, Inc. (TGTX) is a distinguished biopharmaceutical company headquartered in New York, focused on developing and commercializing novel therapies for B-cell malignancies and autoimmune diseases. The company boasts a diverse pipeline of innovative product candidates, utilizing cutting-edge drug development technologies that solidify its stance as a front-runner in oncology and autoimmune treatment sectors. Driven by a mission to fulfill unmet medical needs, TG Therapeutics is comm...

GNG Research Analysis

GNG Research scores TG Therapeutics Inc (TGTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for TGTX.

Frequently Asked Questions

Does TGTX pay dividends?

TG Therapeutics Inc (TGTX) does not currently pay a regular dividend.

What is TGTX's P/E ratio?

TG Therapeutics Inc has a price-to-earnings (P/E) ratio of 13.08.

What is TGTX's market cap?

TG Therapeutics Inc (TGTX) has a market capitalization of $5.73B with a current stock price of $36.64.